Premier Biomedical Secures Key Patent On Feldetrex. Studies Underway for New Fibromyalgia Medication
Press Release: June 30, 2014
Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer’s disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication “Feldetrex ™”, which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future.
President and CEO, William A. Hartman, stated, “We are very excited that the United States Patent Office granted our request for a patent on Feldetrex ™. We are very confident in our ability to perform well in the upcoming double-blind clinical study because of the favorable responses we have received to date from the limited number of patients that have taken the medication thus far. We are applying for FDA approval immediately and are also confident that our application will be approved, since Feldetrex ™ consists only of a skillful and proprietary combination of FDA-approved ingredients. The market for such a medication worldwide runs into many billions of dollars. We believe that our medication will also fare very well versus competition due to its projected lack of serious side effects. The market should see results very quickly as the double-blind study is tentatively scheduled to be concluded later this calendar year.”
More About Premier Biomedical Inc and Feldetrex:
Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for a variety of medical conditions, recently announced that the U.S. Patent Office approved a patent on its proprietary medication Feldetrex™, which is designed to relieve the symptoms of neuropathic pain and fibromyalgia.
In the near future, the William Beaumont Army Medical Center Principal Investigator will draft a protocol for a double-blind, placebo-controlled comparison of Feldetrex™ and a leading FDA-approved regimen. The early-stage clinical trials should provide management and investors with key insights into the safety and efficacy of the treatment compared to options that are already available on the market.